Hold Rating for VYNE Therapeutics Amid Strategic Shift and Clinical Uncertainty Following Yarrow Bioscience Merger

H.C. Wainwright analyst Joseph Pantginis has reiterated their neutral stance on VYNE stock, giving a Hold rating on December 9.

Joseph Pantginis has given his Hold rating due to a combination of factors stemming from VYNE Therapeutics’ recent merger with Yarrow Bioscience. The merger marks a strategic shift for VYNE, as it redirects focus away from its own therapeutic candidates, VYN201 and VYN202, which faced major clinical setbacks. Instead, the newly combined company will center its efforts on Yarrow’s lead clinical candidate, YB-101, aimed at treating Graves’ disease and thyroid eye disease, with early-stage clinical trials anticipated in the coming years. While this merger provides some financial stability and a fresh clinical direction, further details about the success and progress of YB-101 remain to be seen.
Pantginis maintains his Neutral rating as the long-term potential of the Yarrow Bioscience merger is still uncertain. Positive factors such as the $200 million in financing to support operations until 2028 and YB-101 entering advanced stages of clinical trials are promising, but significant risk remains, tied to the clinical success of Yarrow’s pipeline and potential funding challenges. For now, Pantginis and his team will monitor developments closely as they assess Yarrow’s broader strategy and the viability of its therapeutic programs.

In another report released on December 9, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $0.36 price target.